The effect of a simulated commercial flight environment with hypoxia and low humidity on clotting, platelet, and endothelial function in participants with type 2 diabetes - A cross-over study

Judit Konya, Ahmed Al Qaissi, Thozhukat Sathyapalan, Ramzi Ajjan, Leigh Madden, Khalid M. Naseem, Andrew Thomas Garrett, Eric Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: To determine if clotting, platelet, and endothelial function were affected by simulated short-haul commercial air flight conditions (SF) in participants with type 2 diabetes (T2DM) compared to controls. Methods: 10 participants with T2DM (7 females, 3 males) and 10 controls (3 females, 7 males) completed the study. Participants were randomized to either spend 2 h in an environmental chamber at sea level conditions (temperature: 23°C, oxygen concentration 21%, humidity 45%), or subject to a simulated 2-h simulated flight (SF: temperature: 23°C, oxygen concentration 15%, humidity 15%), and crossed over 7 days later. Main outcome measures: clot formation and clot lysis parameters, functional platelet activation markers, and endothelial function measured by reactive hyperemia index (RHI) by EndoPAT and serum microparticles. Results: Comparing baseline with SF conditions, clot maximal absorption was increased in controls (0.375 ± 0.05 vs. 0.39 ± 0.05, p < 0.05) and participants with T2DM (0.378 ± 0.089 vs. 0.397 ± 0.089, p < 0.01), while increased basal platelet activation for both fibrinogen binding and P-selectin expression (p < 0.05) was seen in participants with T2DM. Parameters of clot formation and clot lysis, stimulated platelet function (stimulated platelet response to ADP and sensitivity to prostacyclin), and endothelial function were unchanged. Conclusion: While SF resulted in the potential of denser clot formation with enhanced basal platelet activation in T2DM, the dynamic clotting, platelet, and endothelial markers were not affected, suggesting that short-haul commercial flying adds no additional hazard for venous thromboembolism for participants with T2DM compared to controls.

Original languageEnglish
Article number26
JournalFrontiers in Endocrinology
Volume9
Issue numberFEB
DOIs
Publication statusPublished - 13 Feb 2018

Fingerprint

Humidity
Cross-Over Studies
Type 2 Diabetes Mellitus
Platelet Activation
Blood Platelets
Oxygen
Temperature
P-Selectin
Venous Thromboembolism
Hyperemia
Epoprostenol
Oceans and Seas
Adenosine Diphosphate
Fibrinogen
Air
Outcome Assessment (Health Care)
Hypoxia
Serum

Keywords

  • Clotting
  • Endothelial function
  • Flight simulation
  • Hypoxia
  • Platelet function
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

The effect of a simulated commercial flight environment with hypoxia and low humidity on clotting, platelet, and endothelial function in participants with type 2 diabetes - A cross-over study. / Konya, Judit; Al Qaissi, Ahmed; Sathyapalan, Thozhukat; Ajjan, Ramzi; Madden, Leigh; Naseem, Khalid M.; Garrett, Andrew Thomas; Kilpatrick, Eric; Atkin, Stephen.

In: Frontiers in Endocrinology, Vol. 9, No. FEB, 26, 13.02.2018.

Research output: Contribution to journalArticle

Konya, Judit ; Al Qaissi, Ahmed ; Sathyapalan, Thozhukat ; Ajjan, Ramzi ; Madden, Leigh ; Naseem, Khalid M. ; Garrett, Andrew Thomas ; Kilpatrick, Eric ; Atkin, Stephen. / The effect of a simulated commercial flight environment with hypoxia and low humidity on clotting, platelet, and endothelial function in participants with type 2 diabetes - A cross-over study. In: Frontiers in Endocrinology. 2018 ; Vol. 9, No. FEB.
@article{8f4699ceeb1548338309c2fe3b986725,
title = "The effect of a simulated commercial flight environment with hypoxia and low humidity on clotting, platelet, and endothelial function in participants with type 2 diabetes - A cross-over study",
abstract = "Aims: To determine if clotting, platelet, and endothelial function were affected by simulated short-haul commercial air flight conditions (SF) in participants with type 2 diabetes (T2DM) compared to controls. Methods: 10 participants with T2DM (7 females, 3 males) and 10 controls (3 females, 7 males) completed the study. Participants were randomized to either spend 2 h in an environmental chamber at sea level conditions (temperature: 23°C, oxygen concentration 21{\%}, humidity 45{\%}), or subject to a simulated 2-h simulated flight (SF: temperature: 23°C, oxygen concentration 15{\%}, humidity 15{\%}), and crossed over 7 days later. Main outcome measures: clot formation and clot lysis parameters, functional platelet activation markers, and endothelial function measured by reactive hyperemia index (RHI) by EndoPAT and serum microparticles. Results: Comparing baseline with SF conditions, clot maximal absorption was increased in controls (0.375 ± 0.05 vs. 0.39 ± 0.05, p < 0.05) and participants with T2DM (0.378 ± 0.089 vs. 0.397 ± 0.089, p < 0.01), while increased basal platelet activation for both fibrinogen binding and P-selectin expression (p < 0.05) was seen in participants with T2DM. Parameters of clot formation and clot lysis, stimulated platelet function (stimulated platelet response to ADP and sensitivity to prostacyclin), and endothelial function were unchanged. Conclusion: While SF resulted in the potential of denser clot formation with enhanced basal platelet activation in T2DM, the dynamic clotting, platelet, and endothelial markers were not affected, suggesting that short-haul commercial flying adds no additional hazard for venous thromboembolism for participants with T2DM compared to controls.",
keywords = "Clotting, Endothelial function, Flight simulation, Hypoxia, Platelet function, Type 2 diabetes",
author = "Judit Konya and {Al Qaissi}, Ahmed and Thozhukat Sathyapalan and Ramzi Ajjan and Leigh Madden and Naseem, {Khalid M.} and Garrett, {Andrew Thomas} and Eric Kilpatrick and Stephen Atkin",
year = "2018",
month = "2",
day = "13",
doi = "10.3389/fendo.2018.00026",
language = "English",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - The effect of a simulated commercial flight environment with hypoxia and low humidity on clotting, platelet, and endothelial function in participants with type 2 diabetes - A cross-over study

AU - Konya, Judit

AU - Al Qaissi, Ahmed

AU - Sathyapalan, Thozhukat

AU - Ajjan, Ramzi

AU - Madden, Leigh

AU - Naseem, Khalid M.

AU - Garrett, Andrew Thomas

AU - Kilpatrick, Eric

AU - Atkin, Stephen

PY - 2018/2/13

Y1 - 2018/2/13

N2 - Aims: To determine if clotting, platelet, and endothelial function were affected by simulated short-haul commercial air flight conditions (SF) in participants with type 2 diabetes (T2DM) compared to controls. Methods: 10 participants with T2DM (7 females, 3 males) and 10 controls (3 females, 7 males) completed the study. Participants were randomized to either spend 2 h in an environmental chamber at sea level conditions (temperature: 23°C, oxygen concentration 21%, humidity 45%), or subject to a simulated 2-h simulated flight (SF: temperature: 23°C, oxygen concentration 15%, humidity 15%), and crossed over 7 days later. Main outcome measures: clot formation and clot lysis parameters, functional platelet activation markers, and endothelial function measured by reactive hyperemia index (RHI) by EndoPAT and serum microparticles. Results: Comparing baseline with SF conditions, clot maximal absorption was increased in controls (0.375 ± 0.05 vs. 0.39 ± 0.05, p < 0.05) and participants with T2DM (0.378 ± 0.089 vs. 0.397 ± 0.089, p < 0.01), while increased basal platelet activation for both fibrinogen binding and P-selectin expression (p < 0.05) was seen in participants with T2DM. Parameters of clot formation and clot lysis, stimulated platelet function (stimulated platelet response to ADP and sensitivity to prostacyclin), and endothelial function were unchanged. Conclusion: While SF resulted in the potential of denser clot formation with enhanced basal platelet activation in T2DM, the dynamic clotting, platelet, and endothelial markers were not affected, suggesting that short-haul commercial flying adds no additional hazard for venous thromboembolism for participants with T2DM compared to controls.

AB - Aims: To determine if clotting, platelet, and endothelial function were affected by simulated short-haul commercial air flight conditions (SF) in participants with type 2 diabetes (T2DM) compared to controls. Methods: 10 participants with T2DM (7 females, 3 males) and 10 controls (3 females, 7 males) completed the study. Participants were randomized to either spend 2 h in an environmental chamber at sea level conditions (temperature: 23°C, oxygen concentration 21%, humidity 45%), or subject to a simulated 2-h simulated flight (SF: temperature: 23°C, oxygen concentration 15%, humidity 15%), and crossed over 7 days later. Main outcome measures: clot formation and clot lysis parameters, functional platelet activation markers, and endothelial function measured by reactive hyperemia index (RHI) by EndoPAT and serum microparticles. Results: Comparing baseline with SF conditions, clot maximal absorption was increased in controls (0.375 ± 0.05 vs. 0.39 ± 0.05, p < 0.05) and participants with T2DM (0.378 ± 0.089 vs. 0.397 ± 0.089, p < 0.01), while increased basal platelet activation for both fibrinogen binding and P-selectin expression (p < 0.05) was seen in participants with T2DM. Parameters of clot formation and clot lysis, stimulated platelet function (stimulated platelet response to ADP and sensitivity to prostacyclin), and endothelial function were unchanged. Conclusion: While SF resulted in the potential of denser clot formation with enhanced basal platelet activation in T2DM, the dynamic clotting, platelet, and endothelial markers were not affected, suggesting that short-haul commercial flying adds no additional hazard for venous thromboembolism for participants with T2DM compared to controls.

KW - Clotting

KW - Endothelial function

KW - Flight simulation

KW - Hypoxia

KW - Platelet function

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85042504762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042504762&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00026

DO - 10.3389/fendo.2018.00026

M3 - Article

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - FEB

M1 - 26

ER -